Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free TMO Stock Alerts

Thermo Fisher Scientific (TMO) Competitors

Thermo Fisher Scientific logo
$492.34 +5.12 (+1.05%)
Closing price 05/29/2026 03:59 PM Eastern
Extended Trading
$493.30 +0.96 (+0.19%)
As of 05/29/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TMO vs. MEDP, A, AMN, BIO, and BIO.B

Should you buy Thermo Fisher Scientific stock or one of its competitors? MarketBeat compares Thermo Fisher Scientific with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Thermo Fisher Scientific include Medpace (MEDP), Agilent Technologies (A), AMN Healthcare Services (AMN), Bio-Rad Laboratories (BIO), and Bio-Rad Laboratories (BIO.B). These companies are all part of the "medical" sector.

How does Thermo Fisher Scientific compare to Medpace?

Thermo Fisher Scientific (NYSE:TMO) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

In the previous week, Thermo Fisher Scientific had 5 more articles in the media than Medpace. MarketBeat recorded 36 mentions for Thermo Fisher Scientific and 31 mentions for Medpace. Thermo Fisher Scientific's average media sentiment score of 1.29 beat Medpace's score of 0.28 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Thermo Fisher Scientific
27 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Medpace
5 Very Positive mention(s)
1 Positive mention(s)
24 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Thermo Fisher Scientific has higher revenue and earnings than Medpace. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$44.56B4.11$6.70B$18.1927.07
Medpace$2.53B5.05$451.12M$15.9128.10

89.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 0.3% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Thermo Fisher Scientific currently has a consensus target price of $616.10, indicating a potential upside of 25.14%. Medpace has a consensus target price of $467.08, indicating a potential upside of 4.47%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, equities analysts plainly believe Thermo Fisher Scientific is more favorable than Medpace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Thermo Fisher Scientific
0 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
2 Strong Buy rating(s)
2.96
Medpace
1 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.20

Medpace has a net margin of 17.19% compared to Thermo Fisher Scientific's net margin of 15.15%. Medpace's return on equity of 120.89% beat Thermo Fisher Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
Thermo Fisher Scientific15.15% 16.86% 8.15%
Medpace 17.19%120.89%24.79%

Thermo Fisher Scientific has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Medpace has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

Summary

Thermo Fisher Scientific beats Medpace on 10 of the 17 factors compared between the two stocks.

How does Thermo Fisher Scientific compare to Agilent Technologies?

Thermo Fisher Scientific (NYSE:TMO) and Agilent Technologies (NYSE:A) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

Thermo Fisher Scientific pays an annual dividend of $1.88 per share and has a dividend yield of 0.4%. Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.8%. Thermo Fisher Scientific pays out 10.3% of its earnings in the form of a dividend. Agilent Technologies pays out 20.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Thermo Fisher Scientific has raised its dividend for 8 consecutive years and Agilent Technologies has raised its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 0.3% of Thermo Fisher Scientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Agilent Technologies has a net margin of 19.55% compared to Thermo Fisher Scientific's net margin of 15.15%. Agilent Technologies' return on equity of 24.33% beat Thermo Fisher Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
Thermo Fisher Scientific15.15% 16.86% 8.15%
Agilent Technologies 19.55%24.33%12.99%

Thermo Fisher Scientific has higher revenue and earnings than Agilent Technologies. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$44.56B4.11$6.70B$18.1927.07
Agilent Technologies$6.95B5.51$1.30B$4.9827.19

In the previous week, Agilent Technologies had 10 more articles in the media than Thermo Fisher Scientific. MarketBeat recorded 46 mentions for Agilent Technologies and 36 mentions for Thermo Fisher Scientific. Thermo Fisher Scientific's average media sentiment score of 1.29 beat Agilent Technologies' score of 0.84 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Thermo Fisher Scientific
27 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Agilent Technologies
18 Very Positive mention(s)
8 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Thermo Fisher Scientific currently has a consensus target price of $616.10, suggesting a potential upside of 25.14%. Agilent Technologies has a consensus target price of $162.79, suggesting a potential upside of 20.24%. Given Thermo Fisher Scientific's higher probable upside, equities analysts clearly believe Thermo Fisher Scientific is more favorable than Agilent Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Thermo Fisher Scientific
0 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
2 Strong Buy rating(s)
2.96
Agilent Technologies
0 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
3.07

Thermo Fisher Scientific has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Summary

Agilent Technologies beats Thermo Fisher Scientific on 10 of the 19 factors compared between the two stocks.

How does Thermo Fisher Scientific compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Thermo Fisher Scientific (NYSE:TMO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

AMN Healthcare Services currently has a consensus price target of $25.29, suggesting a potential downside of 13.09%. Thermo Fisher Scientific has a consensus price target of $616.10, suggesting a potential upside of 25.14%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Thermo Fisher Scientific is more favorable than AMN Healthcare Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AMN Healthcare Services
2 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.22
Thermo Fisher Scientific
0 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
2 Strong Buy rating(s)
2.96

In the previous week, Thermo Fisher Scientific had 25 more articles in the media than AMN Healthcare Services. MarketBeat recorded 36 mentions for Thermo Fisher Scientific and 11 mentions for AMN Healthcare Services. Thermo Fisher Scientific's average media sentiment score of 1.29 beat AMN Healthcare Services' score of 0.22 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AMN Healthcare Services
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Thermo Fisher Scientific
27 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Thermo Fisher Scientific has a net margin of 15.15% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Thermo Fisher Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
AMN Healthcare Services-0.95% 18.01% 5.19%
Thermo Fisher Scientific 15.15%16.86%8.15%

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by company insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Thermo Fisher Scientific has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AMN Healthcare Services$2.73B0.41-$95.70M-$0.87N/A
Thermo Fisher Scientific$44.56B4.11$6.70B$18.1927.07

AMN Healthcare Services has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Summary

Thermo Fisher Scientific beats AMN Healthcare Services on 14 of the 17 factors compared between the two stocks.

How does Thermo Fisher Scientific compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO) and Thermo Fisher Scientific (NYSE:TMO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Thermo Fisher Scientific had 31 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 36 mentions for Thermo Fisher Scientific and 5 mentions for Bio-Rad Laboratories. Thermo Fisher Scientific's average media sentiment score of 1.29 beat Bio-Rad Laboratories' score of 0.00 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bio-Rad Laboratories
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Thermo Fisher Scientific
27 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Bio-Rad Laboratories has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Bio-Rad Laboratories currently has a consensus target price of $303.33, indicating a potential downside of 3.00%. Thermo Fisher Scientific has a consensus target price of $616.10, indicating a potential upside of 25.14%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Thermo Fisher Scientific is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Thermo Fisher Scientific
0 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
2 Strong Buy rating(s)
2.96

Thermo Fisher Scientific has higher revenue and earnings than Bio-Rad Laboratories. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B3.24$759.90M$6.0751.52
Thermo Fisher Scientific$44.56B4.11$6.70B$18.1927.07

Thermo Fisher Scientific has a net margin of 15.15% compared to Bio-Rad Laboratories' net margin of 6.52%. Thermo Fisher Scientific's return on equity of 16.86% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories6.52% 3.56% 2.49%
Thermo Fisher Scientific 15.15%16.86%8.15%

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Thermo Fisher Scientific beats Bio-Rad Laboratories on 14 of the 17 factors compared between the two stocks.

How does Thermo Fisher Scientific compare to Bio-Rad Laboratories?

Thermo Fisher Scientific (NYSE:TMO) and Bio-Rad Laboratories (NYSE:BIO.B) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

In the previous week, Thermo Fisher Scientific had 35 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 36 mentions for Thermo Fisher Scientific and 1 mentions for Bio-Rad Laboratories. Thermo Fisher Scientific's average media sentiment score of 1.29 beat Bio-Rad Laboratories' score of 0.00 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Thermo Fisher Scientific
27 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Bio-Rad Laboratories
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

89.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Thermo Fisher Scientific has higher revenue and earnings than Bio-Rad Laboratories. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$44.56B4.11$6.70B$18.1927.07
Bio-Rad Laboratories$2.58B3.15$759.90M$6.0750.11

Thermo Fisher Scientific presently has a consensus price target of $616.10, suggesting a potential upside of 25.14%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, equities analysts clearly believe Thermo Fisher Scientific is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Thermo Fisher Scientific
0 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
2 Strong Buy rating(s)
2.96
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Thermo Fisher Scientific has a net margin of 15.15% compared to Bio-Rad Laboratories' net margin of 6.52%. Thermo Fisher Scientific's return on equity of 16.86% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Thermo Fisher Scientific15.15% 16.86% 8.15%
Bio-Rad Laboratories 6.52%3.56%2.49%

Thermo Fisher Scientific has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Summary

Thermo Fisher Scientific beats Bio-Rad Laboratories on 14 of the 17 factors compared between the two stocks.

Get Thermo Fisher Scientific News Delivered to You Automatically

Sign up to receive the latest news and ratings for TMO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TMO vs. The Competition

Export
MetricThermo Fisher ScientificMED INSTRUMENTS IndustryMedical SectorNYSE Exchange
Market Cap$183.03B$7.21B$5.96B$22.74B
Dividend Yield0.38%1.34%2.69%4.08%
P/E Ratio27.0746.5121.4130.62
Price / Sales4.1187.39626.5515.47
Price / Cash16.2024.6443.2225.14
Price / Book3.467.3210.554.79
Net Income$6.70B$158.10M$3.56B$1.07B
7 Day Performance9.76%4.10%2.85%1.14%
1 Month Performance2.65%10.63%4.59%1.26%
1 Year Performance22.35%4.45%37.62%28.06%

Thermo Fisher Scientific Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TMO
Thermo Fisher Scientific
4.9065 of 5 stars		$492.34
+1.1%		$616.10
+25.1%		+22.3%$183.03B$44.56B27.07125,000
MEDP
Medpace
2.2991 of 5 stars		$432.80
flat		$467.08
+7.9%		+50.8%$12.36B$2.53B27.206,200
A
Agilent Technologies
4.8078 of 5 stars		$115.01
+0.0%		$163.71
+42.4%		+21.1%$32.50B$6.95B25.3918,100
AMN
AMN Healthcare Services
1.6306 of 5 stars		$27.65
0.0%		$25.29
-8.6%		+38.0%$1.07B$3.42BN/A2,664
BIO
Bio-Rad Laboratories
0.5783 of 5 stars		$288.55
+0.3%		$303.33
+5.1%		+37.9%$7.72B$2.59B47.547,450

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:TMO) was last updated on 5/31/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel